- Trials with a EudraCT protocol (833)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (8)
833 result(s) found for: Factor X.
Displaying page 1 of 42.
EudraCT Number: 2009-011145-18 | Sponsor Protocol Number: TEN01 | Start Date*: 2009-11-02 | |||||||||||
Sponsor Name:Bio Products Laboratory Ltd | |||||||||||||
Full Title: A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency | |||||||||||||
Medical condition: Factor X deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003093-98 | Sponsor Protocol Number: Ten02 | Start Date*: 2015-02-24 |
Sponsor Name:Bio Products Laboratory Limited | ||
Full Title: A Phase III Open, Multicentre Study to Confirm the Safety, Pharmacokinetics and Efficacy of BPL’s High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of... | ||
Medical condition: Factor X Deficiency | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-015086-31 | Sponsor Protocol Number: Ten03 | Start Date*: 2010-03-16 |
Sponsor Name:Bio Products Laboratory Limited | ||
Full Title: Ten03: A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL’s High Purity Factor X in the treatment of the Factor X Deficient Subjects Undergoing Surgery | ||
Medical condition: Factor X Deficiency | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-000382-19 | Sponsor Protocol Number: BE1116_3001 | Start Date*: 2005-09-15 | |||||||||||
Sponsor Name:ZLB Behring GmbH | |||||||||||||
Full Title: Efficacy and tolerance of BERIPLEX® P/N in subjects with acquired deficiency of coagulation factors II, VII, IX and X due to oral anticoagulation | |||||||||||||
Medical condition: Acquired deficiency of coagulation factors II, VII, IX and X due to oral anticoagulation requiring an immediate reversal of anticoagulant effect (i.e. emergency surgery or acute bleeding). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) HU (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000806-39 | Sponsor Protocol Number: BAY2599023/19429 | Start Date*: 2019-02-25 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with sever... | |||||||||||||
Medical condition: Hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001079-18 | Sponsor Protocol Number: FLT180a-06 | Start Date*: 2022-04-27 | |||||||||||
Sponsor Name:Freeline Therapeutics Ltd | |||||||||||||
Full Title: A dose confirmation study of FLT180a (adeno-associated viral vector containing the Padua variant of a codon-optimized human Factor IX gene) in adult subjects with hemophilia B. | |||||||||||||
Medical condition: Haemophilia B. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004451-37 | Sponsor Protocol Number: C3731003 | Start Date*: 2021-09-24 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Sev... | |||||||||||||
Medical condition: hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Completed) ES (Restarted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019250-41 | Sponsor Protocol Number: 220901 | Start Date*: 2010-05-27 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: AN INTERNATIONAL, MULTI-CENTRE, PROSPECTIVE, OPEN-LABEL, NON-RANDOMISED, UNCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROTHROMPLEX TOTAL IN ORAL ANTICOAGULANT REVERSAL IN PATIENTS WITH A... | |||||||||||||
Medical condition: Acquired Deficiency of Prothrombin Complex Coagulation Factors (II, VII, IX, X) due to oral anticoagulant therapy with Vitamin K antagonists | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002866-21 | Sponsor Protocol Number: BH29884 | Start Date*: 2016-01-11 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS ... | ||||||||||||||||||
Medical condition: Hemophilia A with Inhibitors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000739-28 | Sponsor Protocol Number: CT-AMT-060-04_(CSL220_1002) | Start Date*: 2020-11-19 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered t... | |||||||||||||
Medical condition: Haemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Trial now transitioned) DK (Prematurely Ended) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004858-30 | Sponsor Protocol Number: BAY94-9027/21824 | Start Date*: 2022-09-05 | ||||||||||||||||
Sponsor Name:Bayer Consumer Care AG | ||||||||||||||||||
Full Title: A phase 3, single group treatment, open-label, study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years wit... | ||||||||||||||||||
Medical condition: Severe hemophilia A (<1% FVIII:C) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: NO (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004305-40 | Sponsor Protocol Number: CSL222-3001 | Start Date*: 2018-10-12 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene ... | |||||||||||||
Medical condition: Hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000826-31 | Sponsor Protocol Number: NN7999-3774 | Start Date*: 2012-08-24 | |||||||||||
Sponsor Name:Novo Nordisk | |||||||||||||
Full Title: Safety, Efficacy and Pharmacokinetics of NNC-0156- 0000-0009 (N9-GP) in Previously Treated Children with Haemophilia B | |||||||||||||
Medical condition: Haemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023072-17 | Sponsor Protocol Number: NN7999-3775 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B | |||||||||||||
Medical condition: Haemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) GB (Completed) NL (Completed) DE (Completed) IT (Completed) ES (Completed) AT (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000985-21 | Sponsor Protocol Number: Bay14-2222/12800 | Start Date*: 2009-12-07 | |||||||||||
Sponsor Name:Bayer HealthCare Pharmaceuticals Inc | |||||||||||||
Full Title: Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compa... | |||||||||||||
Medical condition: Hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005489-37 | Sponsor Protocol Number: CSL654_3003 | Start Date*: 2014-07-11 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B | |||||||||||||
Medical condition: Hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) CZ (Completed) BG (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000219-24 | Sponsor Protocol Number: 3082A-101342 | Start Date*: 2005-04-28 |
Sponsor Name:Wyeth Pharmaceuticals | ||
Full Title: A multicentre study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital haemophilia A who develop de novo factor VIII inhibitors while receiving fac... | ||
Medical condition: Haemophilia A is an X-linked recessive clotting disorder in which the clotting factor, factor VIII (FVIII), is deficient or inactive. Patients with low levels of FVIII have an increased tendency t... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Prematurely Ended) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004366-25 | Sponsor Protocol Number: MO39129 | Start Date*: 2017-10-09 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS | ||||||||||||||||||
Medical condition: Hemophilia A | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) DK (Prematurely Ended) HU (Completed) ES (Completed) PL (Completed) FI (Completed) BE (Completed) SE (Completed) NL (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002333-34 | Sponsor Protocol Number: CSL654_3004 | Start Date*: 2024-05-01 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Chinese Su... | |||||||||||||
Medical condition: Hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021781-29 | Sponsor Protocol Number: BAY81-8973/13400 | Start Date*: 2011-07-07 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A multicenter Phase III uncontrolled open-label trial to evaluate safety and efficacy of BAY 81-8973 in children with severe haemophilia A under prophylaxis therapy | |||||||||||||
Medical condition: Severe Hemophilia-A (< 1% FVIII:C) | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: HU (Completed) LT (Completed) SE (Completed) DK (Completed) IE (Completed) LV (Completed) BG (Completed) IT (Completed) PL (Completed) AT (Completed) ES (Completed) GB (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
